Article thumbnail

Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases

By Carsten Nieder, Ellinor Haukland, Adam Pawinski and Astrid Dalhaug
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2894796
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2004). Canby-Hagino E: Anemia in men with advanced prostate cancer: incidence, etiology, and treatment. Rev Urol
  2. (2009). Chemotherapy in patients with castration-resistant prostate cancer.
  3. (2007). Complications arising fin the final year of life in men dying from advanced prostate cancer.
  4. (2009). Engert A: Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet
  5. (2009). Fosså SD: Initial management of prostate cancer: first year experience with the Norwegian National Prostate Cancer Registry.
  6. (2008). Gornet MK: Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review. Aging Male
  7. (1996). Haematological variables in prostatic carcinoma patients. Acta Urol Belg
  8. (2007). Lichtin AE, American Society of Clinical Oncology; American Society of Hematology: Use of epoetin and darbepoetin in patients with cancer:
  9. (2004). Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of Southwest Oncology Group Study 8894. J Urol
  10. (2008). Simple stratification of survival using bone scan and serum Creactive protein in prostate cancer patients with metastases. Urol Int
  11. (2006). Southwest Oncology Group: The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894. Cancer
  12. (2003). Vogelzang NJ: Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.